Helix BioPharma Corp. (TSX:HBP)
Canada · Delayed Price · Currency is CAD 1.800
-0.050 (-2.70%)
Sep 4, 2026, 2:37 PM EST
Helix BioPharma Balance Sheet
Financials in millions CAD. Fiscal year is August - July.
Millions CAD. Fiscal year is Aug - Jul.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Apr '26 Apr 30, 2026 | Jul '25 Jul 31, 2025 | Jul '24 Jul 31, 2024 | Jul '23 Jul 31, 2023 | Jul '22 Jul 31, 2022 | Jul '21 Jul 31, 2021 |
Cash & Equivalents | 2.84 | 0.07 | 1.08 | 0.81 | 3.25 | 3.57 |
Cash & Short-Term Investments | 2.84 | 0.07 | 1.08 | 0.81 | 3.25 | 3.57 |
Cash Growth | 297.48% | -93.99% | 33.79% | -75.15% | -8.78% | -15.82% |
Other Receivables | 0.03 | 0.12 | 0.05 | 0.06 | 0.28 | 0.35 |
Receivables | 0.03 | 0.12 | 0.05 | 0.06 | 0.28 | 0.35 |
Prepaid Expenses | 0.12 | 0.22 | 0.32 | 0.13 | 0.16 | 0.1 |
Total Current Assets | 2.99 | 0.41 | 1.46 | 1 | 3.7 | 4.02 |
Property, Plant & Equipment | 0 | 0 | 0.03 | 0.03 | 0.04 | 0.05 |
Other Intangible Assets | 18.39 | 18.39 | 0 | - | - | - |
Total Assets | 21.38 | 18.8 | 1.49 | 1.03 | 3.73 | 4.07 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Apr '26 Apr 30, 2026 | Jul '25 Jul 31, 2025 | Jul '24 Jul 31, 2024 | Jul '23 Jul 31, 2023 | Jul '22 Jul 31, 2022 | Jul '21 Jul 31, 2021 |
Accounts Payable | 2.5 | 2.3 | 0.86 | 0.49 | 0.6 | 1.47 |
Accrued Expenses | 0.16 | 0.58 | 0.72 | 0.38 | 0.35 | 0.38 |
Short-Term Debt | 0.36 | 0.34 | - | - | - | - |
Current Portion of Long-Term Debt | - | - | - | - | 2.47 | 2.03 |
Current Portion of Leases | 0 | 0 | - | - | - | - |
Other Current Liabilities | 3.67 | - | - | 1 | -0 | - |
Total Current Liabilities | 6.69 | 3.22 | 1.58 | 1.87 | 3.41 | 3.87 |
Long-Term Debt | - | - | - | - | - | 1.58 |
Other Long-Term Liabilities | - | - | - | - | 0 | - |
Total Liabilities | 6.69 | 3.22 | 1.58 | 1.87 | 3.41 | 5.46 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Apr '26 Apr 30, 2026 | Jul '25 Jul 31, 2025 | Jul '24 Jul 31, 2024 | Jul '23 Jul 31, 2023 | Jul '22 Jul 31, 2022 | Jul '21 Jul 31, 2021 |
Common Stock | 180.77 | 179.29 | 158.57 | 152.07 | 147.51 | 139.66 |
Additional Paid-In Capital | 49.47 | 48.3 | 47.36 | 44.14 | 37.59 | 27.87 |
Retained Earnings | -218.25 | -215.88 | -210.67 | -201.41 | -195.12 | -188.55 |
Comprehensive Income & Other | 2.7 | 3.87 | 4.65 | 4.36 | 10.34 | 19.63 |
Total Common Equity | 14.69 | 15.59 | -0.09 | -0.85 | 0.32 | -1.39 |
Shareholders' Equity | 14.69 | 15.59 | -0.09 | -0.85 | 0.32 | -1.39 |
Total Liabilities & Equity | 21.38 | 18.8 | 1.49 | 1.03 | 3.73 | 4.07 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Apr '26 Apr 30, 2026 | Jul '25 Jul 31, 2025 | Jul '24 Jul 31, 2024 | Jul '23 Jul 31, 2023 | Jul '22 Jul 31, 2022 | Jul '21 Jul 31, 2021 |
Total Debt | 0.36 | 0.34 | - | - | 2.47 | 3.61 |
Net Cash (Debt) | 2.48 | -0.27 | 1.08 | 0.81 | 0.78 | -0.05 |
Net Cash Growth | 247.13% | - | 33.79% | 3.06% | - | - |
Net Cash Per Share | 0.03 | -0.00 | 0.02 | 0.02 | 0.03 | -0.00 |
Filing Date Shares Outstanding | 76.38 | 76.38 | 49.02 | 43.33 | 34.86 | 28.49 |
Total Common Shares Outstanding | 76.38 | 74.16 | 49.02 | 40 | 34.36 | 28.23 |
Working Capital | -3.7 | -2.81 | -0.12 | -0.88 | 0.28 | 0.14 |
Book Value Per Share | 0.19 | 0.21 | -0.00 | -0.02 | 0.01 | -0.05 |
Tangible Book Value | -3.7 | -2.8 | -0.09 | -0.85 | 0.32 | -1.39 |
Tangible Book Value Per Share | -0.05 | -0.04 | -0.00 | -0.02 | 0.01 | -0.05 |
Machinery | 1.22 | 1.22 | 1.46 | 1.44 | 1.44 | 1.43 |
Leasehold Improvements | - | - | 0.36 | 0.36 | 0.36 | 0.36 |